Abstract Number: 0387 • ACR Convergence 2021
Predictors for Progressive Fibrosis in Patients with Connective Tissue Disease Associated Interstitial Lung Diseases
Background/Purpose: Connective tissue disease associated interstitial lung disease (CTD-ILD) is associated with decreased quality of life and high mortality risk. Outcome and treatment response is…Abstract Number: 0683 • ACR Convergence 2021
Predictors of Rapidly Progressive Interstitial Lung Disease and Mortality in Patients with Autoantibodies Against Melanoma Differentiation-Associated Protein 5 Dermatomyositis
Background/Purpose: Anti-melanoma differentiation-associated protein 5 (MDA5) positive dermatomyositis (DM) is associated with rapidly progressive interstitial lung disease (RP-ILD) and high mortality. This multi-centre retrospective study…Abstract Number: 1385 • ACR Convergence 2021
Overall Survival in Patients with Systemic Autoimmune Diseases Following Lung or Heart-Lung Transplantation at a Single High-Volume Academic Transplant Center: A Comparative Cohort Study
Background/Purpose: Lung manifestations of systemic autoimmune diseases are a frequent cause of early death. For many patients, current treatments cannot arrest the inexorable progression to…Abstract Number: 1917 • ACR Convergence 2021
Sputum TGF-β1 Is Elevated in Subclinical and Clinically Significant Rheumatoid Arthritis-Associated Interstitial Lung Disease and Correlates with Soluble IL-6R Levels
Background/Purpose: Increased levels of transforming growth factor β1 (TGF-β1) in the lung have been implicated in the pathogenesis of several fibrotic lung diseases, but their…Abstract Number: 0389 • ACR Convergence 2021
Use of Nintedanib for the Treatment of Systemic Sclerosis-associated Interstitial Lung Disease at Expert Scleroderma Centers in the United States
Background/Purpose: Interstitial lung disease (ILD) affects 40-60% of adults with systemic sclerosis (SSc) and is the leading cause of death in this population. Nintedanib, a…Abstract Number: 0684 • ACR Convergence 2021
Extended Report: Successful Treatment anti-MDA5 Antibody-positive Interstitial Lung Disease with Plasma Exchange Therapy
Background/Purpose: This study was extended report from our previous study that “Successful treatment of anti-MDA5 antibody-positive refractory interstitial lung disease with plasma exchange therapy” (Rheumatology…Abstract Number: 1389 • ACR Convergence 2021
Subclinical ILD Is Frequent and Progresses Across Different Connective Tissue Diseases
Background/Purpose: Based on the argument that symptoms-define-disease, physicians commonly apply the terms pre-clinical or sub-clinical disease to describe patients with disease-related findings, but no accompanying…Abstract Number: 1918 • ACR Convergence 2021
Don’t Forget About the Arthritis in RA-ILD! Impact of Pulmonary and RA Disease Severity on Survival
Background/Purpose: Long-term outcomes following a diagnosis of rheumatoid arthritis associated interstitial lung disease (RA-ILD) are poor, with a median survival estimated between 3 to 8…Abstract Number: 0008 • ACR Convergence 2021
Jo-1-Binding and Clonally-Expanded Memory B Cells Express Germline and Somatically-Mutated B Cell Receptors in Anti-tRNA Synthetase Syndrome Patients
Background/Purpose: Anti-tRNA synthetase syndrome (ARS) is a severe systemic autoimmune disease associated with myositis, interstitial lung disease, rash, and arthritis. ARS is associated with autoantibodies…Abstract Number: 0393 • ACR Convergence 2021
Severity and Impact of Gastrointestinal Symptoms in Patients with SSc-ILD Treated with Nintedanib: Data from SENSCIS-ON
Background/Purpose: Gastrointestinal (GI) involvement is a common manifestation of systemic sclerosis (SSc) and a frequent side-effect of drugs used to treat SSc. In the SENSCIS…Abstract Number: 0704 • ACR Convergence 2021
Anti-SSa/SSb and Ro52 and Interstitial Lung Disease in Idiopathic Inflammatory Myopathies
Background/Purpose: In idiopathic inflammatory myopathies (IIM), SSa/SSb and Ro52 antibodies are frequently reported, especially in association with interstitial lung disease (ILD). However, limited literature exists…Abstract Number: 1390 • ACR Convergence 2021
A 5% Increase in Interstitial Lung Disease at 1-Year Follow-up Is Associated with Long-Term ILD Progression in Systemic Sclerosis
Background/Purpose: The clinical course of interstitial lung disease (ILD) in systemic sclerosis (SSc) is highly variable. Some patients experience a progressive decline in lung function…Abstract Number: 1930 • ACR Convergence 2021
Single-Cell Genomics Reveals a Shared Monocyte Interferon Program in a Subset of Patients with Systemic Juvenile Idiopathic Arthritis, Macrophage Activation Syndrome and Lung Disease
Background/Purpose: Systemic juvenile idiopathic arthritis (SJIA) is a clinically heterogenous disease and can be complicated by macrophage activation syndrome (MAS) and lung disease (LD) thought…Abstract Number: 0469 • ACR Convergence 2020
IFNγ Is Essential for Alveolar Macrophage Driven Lung Inflammation in Macrophage Activation Syndrome
Background/Purpose: Macrophage activation syndrome (MAS) is a life-threatening cytokine storm syndrome frequently complicating systemic juvenile idiopathic arthritis (SJIA) and driven by IFNγ. MAS is also…Abstract Number: 1053 • ACR Convergence 2020
Efficacy of Rituximab for Connective Tissue Disease (CTD) Associated Interstitial Lung Disease (ILD) : A Single Center Study of 47 Patients- Extension Study
Background/Purpose: Interstitial lung disease (ILD) is a fatal complication associated with connective tissue diseases (CTDs), often resulting in substantial morbidity and mortality. Despite numerous advances…
- « Previous Page
- 1
- …
- 23
- 24
- 25
- 26
- 27
- …
- 39
- Next Page »